PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.

Abstract The outcomes of locally advanced non-small cell lung cancer (NSCLC) remain poor, in particular, the frail elderly patients cannot tolerate chemotherapy. The new efficient, safe, and more specific treatments are needed. Radiation combined with targeted therapy is the focus of research in recent years. Apatinib is highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, studies have revealed that apatinib inhibit the growth of solid tumors including NSCLC. However, there is no report to evaluate its efficacy and safety in combined with radiotherapy for the advanced NSCLC. Our original research about to explore the use of apatinib combined with radiotherapy in treatment of NSCLC and its side effects are as follows.
PMID
Related Publications

Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.

Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review.

A case report of apatinib in treating osteosarcoma with pulmonary metastases.

Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29390380
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20180212
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 50
DP  - 2017 Dec
TI  - Significant efficacy and well safety of apatinib combined with radiotherapy in
      NSCLC: Case report.
PG  - e9276
LID - 10.1097/MD.0000000000009276 [doi]
AB  - RATIONALE: The outcomes of locally advanced non-small cell lung cancer (NSCLC)
      remain poor, in particular, the frail elderly patients cannot tolerate
      chemotherapy. The new efficient, safe, and more specific treatments are needed.
      Radiation combined with targeted therapy is the focus of research in recent
      years. Apatinib is highly selective tyrosine kinase inhibitor of vascular
      endothelial growth factor receptor-2, studies have revealed that apatinib inhibit
      the growth of solid tumors including NSCLC. However, there is no report to
      evaluate its efficacy and safety in combined with radiotherapy for the advanced
      NSCLC. Our original research about to explore the use of apatinib combined with
      radiotherapy in treatment of NSCLC and its side effects are as follows. PATIENT
      CONCERNS: Patient 1, man, 78-year old, admitted to hospital, due to "thoracalgia 
      and dyspnea for 1 month." Chest and abdomen computed tomography (CT) scan showed 
      that there was a huge mass at the left upper lobe and multiple lymph nodes
      metastasis in mediastinum and left hilus pulmonis, the diagnosis was left lung
      squamous cell carcinoma, however, the mass was huge and age of patient was elder,
      post chemotherapy the mass were bigger and more severe. Patient 2, man, 61-year
      old, the diagnosis was squamous carcinoma on left upper lobe with right
      mediastinum lymph notes metastases recrudescence post chemoradiotherapy.
      DIAGNOSES: Case 1 was diagnosed left lung huge squamous cell carcinoma and case 2
      was left lung squamous carcinoma, the primary lesion and right mediastinum lymph 
      notes metastases recrudescence after radiochemotherapy. INTERVENTIONS: Both
      patients who received local radiation therapy and concurrent apatinib. Apatinib
      250 mg once daily in combination with thoracic radiotherapy (2 Gy/d, 5
      fractions/wk) followed by Apatinib Maintenance Therapy. OUTCOMES: Favorable
      oncologic outcomes were achieved in the 2 cases after the treatment. The common
      side effects of apatinib were hypertension and hand-foot syndrome; however, the
      toxicity of was controllable and tolerable, no dyspnea, no hemoptysis, no
      thoracalgia. LESSONS: Apatinib combined with thoracic radiotherapy, may be an
      option for recurring or advanced NSCLC. But that still warrants further
      investigation in the prospective study.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Zhao, Chunbo
AU  - Zhao C
AD  - Department of Radiation Oncology, The Third Affiliated Hospital of Harbin Medical
      University, Harbin, Heilongjiang Province, China.
FAU - Zhang, Qian
AU  - Zhang Q
FAU - Qiao, Wenbo
AU  - Qiao W
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*radiotherapy
MH  - Combined Modality Therapy
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Pyridines/*therapeutic use
EDAT- 2018/02/03 06:00
MHDA- 2018/02/13 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1097/MD.0000000000009276 [doi]
AID - 00005792-201712150-00130 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(50):e9276. doi: 10.1097/MD.0000000000009276.